Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial

BackgroundConestat alfa (ConA), a recombinant human C1 inhibitor, may prevent thromboinflammation.MethodsWe conducted a randomized, open-label, multi-national clinical trial in which hospitalized adults at risk for progression to severe COVID-19 were assigned in a 2:1 ratio to receive either 3 days...

Full description

Bibliographic Details
Main Authors: Pascal Urwyler, Marina Leimbacher, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi, Michael Osthoff
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
COVID-19
randomized trial
C1 esterase inhibitor
complement system
kallikrein kinin system
contact activation system
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255292/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1255292/full

Similar Items